---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-033145"
form_type: "8-K"
ticker: "SYBX"
cik: "0001527599"
company_name: "SYNLOGIC, INC."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:17:56.494126+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Synlogic discontinues PKU program; Q4 net loss $14.5M, cash $47.7M

## Summary
- Discontinued Synpheny-3 pivotal study of SYNB1934 for PKU; evaluating strategic options.
- Q4 2023 revenue $2.8M (vs $0.1M prior year) from Roche collaboration.
- Q4 net loss $14.5M ($1.71 per share) vs $16.7M ($3.54 per share) prior year.
- Full year 2023 net loss $57.3M ($8.81 per share) vs $66.1M ($13.83) prior year.
- Cash and equivalents $47.7M as of Dec 31, 2023.

## SEC filing metadata
- accession: 0000950170-24-033145
- form_type: 8-K
- ticker: SYBX
- cik: 0001527599
- company_name: SYNLOGIC, INC.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527599/000095017024033145/0000950170-24-033145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527599/000095017024033145/sybx-20240319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-033145
- JSON: https://secwatch.observer/filing/0000950170-24-033145.json
- Plain text: https://secwatch.observer/filing/0000950170-24-033145.txt

## Key facts
- Earnings Releases
  SYNLOGIC, INC. reported the year ended December 31, 2023 results: revenue $3.4 million, net income $57.3 million, EPS $8.81 per share.
  - Period: the year ended December 31, 2023
  - Revenue: $3.4 million
  - Net income: $57.3 million
  - EPS: $8.81 per share
  - Result: reported results
  source text: $1.71 per share, compared to a consolidated net loss of $16.7 million, or $3.54 per share, for the corresponding period in 2022. Full Year 2023 Financial Results Revenues were $3.4 million for the year ended December 31, 2023, compared to $1.2 million for the same period in 2022. Revenue in both periods was associated with the research collaboration with Roche.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527599/000095017024033145/0000950170-24-033145-index.htm
- Earnings Releases
  SYNLOGIC, INC. reported the quarter ended December 31, 2023 results: revenue $2.8 million, net income $14.5 million, EPS $1.71 per share.
  - Period: the quarter ended December 31, 2023
  - Revenue: $2.8 million
  - Net income: $14.5 million
  - EPS: $1.71 per share
  - Result: reported results
  source text: Company. Fourth Quarter 2023 Financial Results As of December 31, 2023, Synlogic had cash, cash equivalents, and short-term marketable securities of $47.7 million. Revenue was $2.8 million for the three months ended December 31, 2023, compared to $0.1 million for the corresponding period in 2022. Revenue in both periods was associated with the research
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527599/000095017024033145/0000950170-24-033145-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.